Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease Summit

Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimer’s disease therapiesCAMBRIDGE, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced participation in the Annual Biomarkers for Alzheimer’s Disease Summit taking place virtually August 25-26, 2021. Chris Winrow, Ph.D., Head of Translational Medicine, will present on biomarker translation and the potential that early clinical assessment of biomarkers has to drive development of Alzheimer’s disease therapies, and Juli Jones, Ph.D., Head of Disease Biology, will be leading a session exploring the utilization of omics platforms in drug discovery.Presentation Details:Title: Exploring the Utilization of Omics Platforms in Drug DiscoveryModerator: Juli Jones Ph.D., Head of Disease Biology, Cyclerion Therapeutics, Inc.Date: Wednesday, August 25, 2021Time: 4:20 p.m. ETTitle: Leading the Vanguard – Early Clinical Assessment of Biomarkers to Drive Development of Alzheimer’s Disease TherapiesPresenter: Chris Winrow, Ph.D., Head of Translational Medicine, Cyclerion Therapeutics, Inc.Date: Thursday, August 26, 2021Time: 2:30 p.m. ET followed by a live Q&A at 3:00 p.m. ETAbout Cyclerion Therapeutics Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function.…
Read More